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Objective. The purpose of this study was to use the electrogram
storage capabilities of the implantable cardioverter-defibrillator
(ICD) to categorize any arrhythmic event during follow-up in a
group of patients who had survived an episode of ventricular
fibrillation (VF) and to possibly identify clinical predictors of
future arrhythmic events.
Background. Little is known about the electrophysiologic char-
acteristics of ventricular arrhythmias recurring during follow-up
in survivors of VF as the sole documented arrhythmia at the time
of resuscitation.
Methods. Forty patients (58 6 10 years; 73% men; left ventric-
ular ejection fraction 42 6 18%; 70% with coronary artery disease)
who had survived an episode of VF and subsequently received an
ICD capable of intracardiac electrogram recording and storage
were followed for 23 6 11 months. In all patients, the arrhythmo-
genic substrate was investigated by means of programmed elec-
trical stimulation (PES).
Results. Among the 40 patients, 41 episodes of ventricular
arrhythmias were documented in 13 patients (33%): 36 episodes of
ventricular tachycardias (VT) were recorded in 11 patients (28%)
and 5 episodes of VF were recorded in the remaining 2 patients
(5%). Age, gender, cardiac disease and left ventricular ejection
fraction failed to distinguish between patients with clinical recur-
rences and patients without. The sensitivity, specificity and posi-
tive accuracy of PES were 29%, 63% and 46%, respectively, for
prediction of ventricular arrhythmia recurrence; 45%, 70% and
36%, respectively, for prediction of VT; and 50%, 98% and 50%,
respectively, for prediction of VF during follow-up.
Conclusions. In survivors of VF receiving ICD therapy, VT is
the most common ventricular arrhythmia recorded on device-
incorporated electrograms during follow-up. This finding, associ-
ated with the relatively well-preserved ventricular function, may
account for the ability of these patients to survive at time of the
index arrhythmia; the use of antitachycardia pacing as a modality
to treat arrhythmia recurrences may contribute to reduce the
incidence of shock during follow-up in these patients.
(J Am Coll Cardiol 1998;32:1724–30)
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At the time of an emergency intervention, victims of out-of-
hospital cardiovascular collapse present with ventricular fibril-
lation (VF) in approximately 40% of cases, with asystole and
electromechanical dissociation becoming more common the
longer the intervention is delayed (1). In situations in which the
time between the clinical event and the first cardiac electro-
gram could be kept under 4 min, the incidence of VF was
found to be 95%; on the other hand, VT was observed during
that time span in only approximately 1% of patients, suggesting
that this arrhythmia does not generally result in cardiovascular
collapse (2).
Other observations support this conclusion. A clinical his-
tory of sustained ventricular tachycardia (VT) has been docu-
mented in only 1% of cardiac arrest survivors (3). Prior to
cardiac arrest, antiarrhythmic drugs were prescribed in only
9.5% of victims, mostly to suppress ventricular ectopy (3). In a
selected group of patients with coronary artery disease (CAD)
receiving external direct-current shock therapy within 30 s of
collapse, VF and VT were the documented rhythms in approx-
imately 90% and 10% of cases, respectively (4).
Presently, little is known about the natural history and
electrophysiologic characteristics of ventricular arrhythmias
recurring during follow-up in survivors of VF as the sole
documented arrhythmia at the time of resuscitation. This
information has mainly been prevented by 1) the tendency to
report under the same category patients with different arrhyth-
mias, such as VT, VF or syncope associated with an inducible
ventricular arrhythmia during programmed electrical stimula-
tion (PES); and 2) the systematic use of antiarrhythmic drug
therapy after the index event (5–16).
Implantable cardioverter-defibrillator (ICD) therapy (17–
21) has enabled us to monitor the occurrence of malignant
ventricular arrhythmias during follow-up in the absence of
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pharmacologic interactions. The ability to retrieve intracardiac
electrograms recorded immediately before, during and imme-
diately after intervention of the device offers new insights into
the clinical history of patients receiving ICD therapy (22–24).
Understanding the arrhythmic profile in patients surviving VF
would be important to better stratify their risk of sudden death;
it would also help to optimize the programming of intervention
modalities in patients receiving ICD therapy.
The purposes of this study were 1) to use the electrogram
storage capabilities of the ICD to document and categorize any
arrhythmic event during follow-up in a group of patients who
had survived an episode of VF as the sole documented
arrhythmia at the time of resuscitation and 2) to possibly
identify predictors of future arrhythmic events.
Methods
Patients. Patients were included in this study if 1) they had
cardiac arrest secondary to documented VF that was not
related to an acute myocardial infarction; 2) VF was the only
arrhythmia documented at the time of cardiac arrest; and 3)
they had an ICD that was capable of intracardiac electrogram
recording and storage. All patients with a prior history of VT
were excluded from this study.
Between November 1991 and January 1995, 40 consecutive
patients who met the inclusion criteria were enrolled.
Mean patient age was 58 6 10 years; 29 patients (73%)
were men. The underlying heart disease was CAD in 28
patients (70%), dilated cardiomyopathy in 5 and mitral valve
prolapse and hypertrophic cardiomyopathy in 1 patient each.
One patient had experienced VF 27 days after repair of an
atrial septal defect. In four patients, no structural heart disease
(idiopathic VF) could be identified by means of physical
examination, 12-lead electrocardiogram (ECG), echocardiog-
raphy, coronary angiography, right and left ventriculography
and nuclear magnetic resonance imaging. Mean left ventricular
ejection fraction (LVEF) was 42 6 18%. Patient characteris-
tics are shown in Table 1.
Baseline electrophysiologic study. All patients underwent
PES prior to ICD implantation. Up to three extrastimuli
(0.5 ms pulse width, twice diastolic threshold) were given at
two right ventricular sites (apex and outflow tract) during sinus
rhythm and basic drive pacing (8 beats) at cycle lengths of 640,
510 and 440 ms. Isoproterenol administration, burst ventricu-
lar pacing and left ventricular stimulation were not used in this
protocol for arrhythmia induction.
Implantable cardioverter-defibrillator. A tiered therapy
ICD was implanted in all patients via a nonthoracotomy
approach. The devices used in this study (Ventak P2 1625,
Ventak PRX II/III 1715/1720, Cardiac Pacemakers Inc. [CPI],
St. Paul, Minnesota) are provided with arrhythmic event
storing capability by means of intracardiac electrogram record-
ing. Rate detection is performed using a bipolar electrode
configuration between the distal coil and the tip electrode of
the lead system (Endotak, CPI) advanced to the right ventric-
ular apex. The defibrillation field is generated between the coil
in the right ventricular apex and a second coil located in the
superior vena cava.
In addition to intracardiac electrogram recording, the de-
vices provide antibradycardia pacing and two to three arrhyth-
mia detection zones. The Ventak P2 is able to discharge
34-joule shocks in the two therapy zones, whereas the Ventak
PRX provides antitachycardia pacing modalities in two to
three zones. According to the characteristics of the target
arrhythmia, only one detection or therapy zone was activated
at the time of hospital discharge. In the present study, the
cut-off rate was set at 180 beats/min or at least 20 beats/min
more than the patient’s maximal sinus rate, as assessed during
Holter monitoring and stress testing. All ICDs were pro-
grammed in an uncommitted mode, thus allowing a charge to
be diverted in the event of spontaneous termination of the
arrhythmia.
Stored intracardiac electrograms. In the Ventak–Endotak
system, the two coils used for shock discharge are connected in
a bipolar configuration to record intracardiac electrograms;
this configuration allows good detection of atrial activation
potentials and of differences in polarity and morphology
between QRS complexes generated during VT and those
generated during sinus rhythm or regular narrow-QRS su-
praventricular tachycardia (25).
The cumulative storing capacity of the devices is 2.5 min for
a maximum of five sensed arrhythmic events. For each event,
intracardiac electrograms can be retrieved from the 10 s
preceding arrhythmia detection, the 10 s preceding device
intervention and the 10 s following the intervention.
Follow-up. Defibrillators were interrogated after all clini-
cally apparent device interventions and on routine follow-up
every 2 to 3 months. In cases of device intervention, all
intracardiac electrograms relating to the intervention were
Abbreviations and Acronyms
AV 5 atrioventricular
CAD 5 coronary artery disease
ICD 5 implantable cardioverter-defibrillator
PES 5 programmed electrical stimulation
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Table 1. Patient Demographics
CAD
(28 patients)
Idiopathic VF
(4 patients)
Others
(8 patients)
Age (yrs) 60 6 8 54 6 17 51 6 10
Gender (male) 23 (82%) 2 (50%) 4 (50%)
LVEF (%) 38 6 16 67 6 9 42 6 17
Prior MI 24 (86%) – –
CAD 5 coronary artery disease; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction; VF 5 ventricular fibrillation. Idiopathic VF
identifies patients in whom the index arrhythmia occurred in the context of no
structural heart disease.
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analyzed. Symptoms before, during and after the intervention
were assessed and classified as syncope in cases of uncon-
sciousness and presyncope in cases of mild to severe dizziness
preceding device intervention.
Arrhythmia classification. Before the analysis of stored
intracardiac electrograms, a current 12-lead ECG was re-
corded from the patient and compared with that recorded at
the time of cardiac arrest and with those available during
follow-up. The intervention-related intracardiac electrogram
was retrieved from the device and the following criteria for
arrhythmia diagnosis were applied.
1. Ventricular fibrillation: An irregular tachycardia with re-
gard to QRS complex polarity, amplitude, morphology and
sequence, and a mean heart rate .250 beats/min.
2. Ventricular tachycardia:
a. Monomorphic: A regular tachycardia with QRS com-
plexes exhibiting one of the following characteristics:
dissociation from clearly detectable P complexes (ven-
triculoatrial dissociation); a significantly different mor-
phology and/or duration ($40 ms) compared with that
observed during sinus rhythm.
b. Polymorphic: An irregular tachycardia with regard to
QRS complex polarity, amplitude, morphology and se-
quence, and a mean heart rate #250 beats/min.
3. Atrial flutter: A regular tachycardia exhibiting no differ-
ences in electrogram QRS morphology and polarity com-
pared with sinus rhythm, and associated with clearly detect-
able P complexes with a fixed or variable, though regular,
degree of atrioventricular (AV) conduction.
4. Atrial fibrillation: An irregular tachycardia exhibiting a
variability of more than 60 ms between consecutive QRS
complexes that was associated with no differences in QRS
morphology compared with sinus rhythm and polarity, and
with no detectable P complexes.
5. Sinus tachycardia: A regular tachycardia exhibiting P and
QRS complexes identical to those recorded during sinus
rhythm, with a mean rate exceeding the programmed cut-off
rate.
In the present study, any stored episode of VF triggered by
one to three consecutive ventricular extrabeats was regarded as
“primary” VF.
Device interventions delivered in the presence of P and
QRS complexes identical to those recorded during sinus
rhythm and with a mean rate lower than the programmed
cut-off rate were regarded as failures in the sense–shock circuit
and led to revision of the defibrillator system. All arrhythmic
episodes that did not meet the criteria for VF or VT were
regarded as nonventricular arrhythmias.
Antiarrhythmic drugs. At the time of hospital discharge
following the index event, antiarrhythmic drugs were not used.
If permanent or paroxysmal supraventricular arrhythmias were
associated with high ventricular rate, antiarrhythmic drugs of
class IV (verapamil) or AV nodal radiofrequency catheter
ablation were used to prevent inappropriate discharges by the
device.
Statistics. Data are presented as median and mean val-
ues 6 SD, where appropriate. Comparisons were made using
SPSS for Windows (version 6.1.2., SPSS). Differences of clin-
ical baseline variables between patient groups with and without
an arrhythmia recurrence were analyzed with Wilcoxon rank-
sum test for continuous but not normally distributed variables
(age, LVEF) and Fisher exact test for categoric variables
(gender, CAD or not). Logistic regression analysis (SPSS for
Windows) was applied to identify independent predictors of
the presence or absence of ventricular arrhythmia detection
during follow-up among these clinical baseline variables. Cycle
lengths of arrhythmia recurrences were analyzed using the
Wilcoxon rank-sum test. Values of p , 0.05 were considered
significant.
Results
Patients were followed for 23 6 11 months (median 22,
range 1 to 45 months). Six patients died after 8 6 8 months
(median 7, range 1 to 20 months): death occurred secondary to
heart failure in five patients (in one patient this was concom-
itant with an acute myocardial infarction, and in another
patient it was perioperative due to heart failure); one patient
died of a lung carcinoma.
Arrhythmia detection. During follow-up, 23 patients
(57%) experienced 101 arrhythmic events (range per patient: 1
to 14 events) that led to an ICD intervention. Stored intracar-
diac electrograms from all episodes could be retrieved and
analyzed. In all cases, the underlying arrhythmias could be
diagnosed according to the criteria mentioned above. Forty-
one episodes of ventricular arrhythmias were documented in
13 patients (33%); 60 episodes of nonventricular arrhythmias
were documented in 13 patients (33%); and 3 patients experi-
enced both ventricular and nonventricular arrhythmia epi-
sodes. Seventeen patients had no ICD interventions during
follow-up. The distribution and cause of ICD therapies deliv-
ered during follow-up are summarized in Table 2 according to
the underlying substrate.
Ventricular fibrillation. Five episodes of VF were ob-
served in two patients (5%); these episodes accounted for 12%
of all ventricular arrhythmic events. In all cases, the arrhythmia
was initiated by one or two premature ventricular beats
(primary VF). One patient had no structural heart disease; the
other had a surgically corrected atrial septal defect. In both
patients, VF was the only arrhythmia documented during
follow-up. In all cases the ventricular arrhythmia was properly
detected by the device and successfully terminated with the
first shock.
Ventricular tachycardia. Eleven patients (28%) experi-
enced a total of 36 episodes of monomorphic VT. In 9 patients
(23%), only VT was observed (Fig. 1), which accounted for 32
of the 36 episodes (i.e., for 78% of all ventricular arrhythmic
events). Mean tachycardia cycle length was 282 6 43 ms
(median 295 ms, range 180 to 330 ms; Fig. 2). Of the 11
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patients, 7 had CAD, 3 had dilated cardiomyopathy and 1 had
no structural heart disease. In the two other patients, four
episodes of VT (i.e., 10% of all ventricular arrhythmic events)
degenerated into VF. In all cases the ventricular arrhythmia
was properly detected by the device and successfully termi-
nated with the first shock.
Nonventricular arrhythmias (Table 2). Of the 60 nonven-
tricular arrhythmic events, atrial fibrillation was responsible for
43 episodes (73%) in 9 patients and atrial flutter for 1 episode
(2%) in another patient; of the former arrhythmia, 13 thera-
pies were recorded in 1 patient during 45 min. Among six
patients with recurrent discharge, control of ventricular rate
was achieved by verapamil administration in four patients and
by AV nodal radiofrequency catheter ablation and pacemaker
implantation in two patients. Four discharges (7%) were
delivered in one patient during sinus tachycardia, exceeding
the programmed cut-off rate. Twelve therapies (20%) were
delivered in four patients, due to failure of the sense–shock
circuit in one and to lead displacement or fracture in three
patients; two patients in the latter group had no structural
heart disease. Inappropriate ICD therapy did not induce
ventricular arrhythmia in any patient.
Clinical presentation of arrhythmic events. The two pa-
tients with primary VF experienced syncope during all five
episodes. During the 36 VT episodes in 11 patients, syncope
was experienced by 1 patient (VT cycle length was 240 ms).
Thirteen episodes of VT (mean cycle length 252 6 46 ms,
median 250 ms, range 180 to 330 ms), including the 4 that
degenerated into VF, were associated with presyncope. Nei-
ther syncope nor presyncope was experienced by any patient
during the remaining 22 episodes of VT, which at 302 6 29 ms
(median 300 ms, range 230 to 330 ms) had a significantly longer
mean cycle length than the VT episodes associated with
presyncope (p , 0.005). The nonventricular events were not
associated with syncope or presyncope. Occurrence of ventric-
ular arrhythmias was homogeneously distributed during
follow-up.
Clinical predictors of arrhythmia detection. Age, gender,
presence of CAD and LVEF failed to distinguish between
patients who experienced clinical recurrences and those who
did not. The two patients with primary VF during follow-up
were 30 and 57 years old and had LVEFs of 79% and 60%,
respectively. Patients with VT had a mean age of 59 6 13 years
and a mean LVEF of 42 6 16%. Patients with ischemic heart
disease and dilated cardiomyopathy did not develop primary
VF during follow-up.
Predictive value of programmed ventricular stimulation.
During baseline PES, a monomorphic VT could be induced in
14 patients (35%, group 1) and VF in 7 patients (18%, group
Figure 1. Intracardiac electrograms retrieved during follow-up from
one patient developing monomorphic VT. Shown are the stored
intracardiac recordings of the 10 s preceding arrhythmia detection (top
panel), the 10 s preceding therapy delivery (middle panel) and the 10 s
following therapy delivery (lower panel). (Top panel) During one
episode of atrial fibrillation, a ventricular extrabeat induces a regular
VT with a heart rate of 225 beats/min. (Middle panel) Ongoing VT.
(Lower panel) After shock delivery, atrial fibrillation is observed.
Figure 2. Distribution of VT cycle lengths recorded by ICD-stored
electrograms during follow-up.
Table 2. Distribution and Cause of Implantable Cardioverter-Defibrillator Therapies During Follow-up
CAD
(7 patients)
Idiopathic VF
(2 patients)
Others
(4 patients)
Total
(13 patients)
Appropriate therapies 21 5 15 41
VT 21 1 14 36
VF 0 4 1 5
(8 patients) (3 patients) (2 patients) (13 patients)
Inappropriate therapies 39 17 4 60
A Fib, A Flutter 28 12 4 44
sinus rhythm 4 0 0 4
system failure 8 4 0 12
A 5 atrial; CAD 5 coronary artery disease; Fib 5 fibrillation; VF 5 ventricular fibrillation; VT 5 ventricular
tachycardia.
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2); no ventricular arrhythmias were inducible in the remaining
19 patients (47%, group 3). The clinical outcome of the general
population and of patients with CAD relative to the response
to PES is reported in Tables 3 and 4, respectively. During
follow-up (Table 3), VT and primary VF occurred in five and
zero patients, respectively, in group I, in zero and one patient,
respectively, in group II, and in six and one patients, respec-
tively, in group III. The sensitivity, specificity and positive and
negative accuracy of PES were 29%, 63%, 46% and 44%,
respectively, for prediction of ventricular arrhythmia recur-
rence, 45%, 70%, 36% and 77%, respectively, for prediction of
VT and 50%, 98%, 50% and 98%, respectively, for prediction
of VF during follow-up.
In the five patients in whom clinical recurrence of VT was
predicted during PES, the tachycardia cycle length during the
electrophysiologic study did not match the one recorded by the
intracardiac electrogram during follow-up.
The one patient in whom VF was predicted during PES had
no structural heart disease.
Underlying substrate and arrhythmia recurrence (Table 2).
Seven of 28 patients (25%) with CAD developed ventricular
arrhythmia recurrence during follow-up; in all cases the docu-
mented arrhythmia was monomorphic VT (Table 4). Of the
four patients with no underlying heart disease, two (50%) had
recurrences. In one patient, the documented arrhythmia was a
monomorphic VT; in the other patient, four episodes of
primary VF were recorded. Among the 8 patients with other
substrates, 15 ventricular arrhythmic events were observed in 4
patients (50%) during follow-up: monomorphic VT accounted
for 14 events and primary VF for 1 event.
Discussion
Major findings of the study. This study shows that in 40
patients treated with an ICD who had survived an episode of
cardiovascular collapse secondary to VF and in whom VF had
been the only ventricular arrhythmia ever documented until
that event, VT rather than VF was the prevailing recurrent
arrhythmia. During a follow-up of approximately 2 years,
primary VF was observed in only 5% of patients, whereas VT
was observed in 28%. Although episodes of primary VF were
always associated with syncope, this hemodynamic conse-
quence accompanied only 1 of 36 episodes of VT. Roughly
one-third of VT episodes, including four that degenerated into
VF, were accompanied by presyncopal attacks, whereas the
remainder of VT episodes did not cause hemodynamic impair-
ment. The VTs of the latter category had a significantly longer
cycle length (corresponding to a mean heart rate of 199
beats/min; number of episodes, 21) than the VTs resulting in
either syncope or presyncope (mean heart rate 239 beats/min;
number of episodes, 13).
The role of VT as the most frequent arrhythmia responsible
for ambulatory sudden collapse and death has been previously
outlined in heterogenous groups of patients undergoing 24-h
Holter monitoring at the time of the terminal event (26).
However, in contrast to the present study, most patients
(approximately 95%) had not experienced ventricular arrhyth-
mias causing cardiac arrest prior to the monitored terminal
event. Therefore, the findings of this study contribute to
further define the clinical profile of survivors of VF as the sole
documented arrhythmia at time of resuscitation.
Recent reports have pointed to different pathophysiologic
and electrophysiologic characteristics between patients pre-
senting with VF and those presenting with regular VT. The
former tend to have a higher ejection fraction (27) and a lower
incidence of late potentials on signal-averaged electrograms
(28), and are less likely to have regular VT induced during PES
(7,13,27–30). Furthermore, induced VTs during PES tend to
be faster and more often polymorphic in patients with docu-
mented VF compared with patients in whom only VT has been
documented (13,29,30). The characteristics of the population
in this study confirm these observations, as suggested by an
LVEF above 40% and a 35% incidence of induced monomor-
phic VT.
Characteristics of recurrent ventricular arrhythmias.
During a follow-up of approximately 2 years, 33% of patients
experienced 1 or more episodes of ventricular arrhythmia.
Notably, 85% of these patients had a VT and only 15% a
primary VF; in the former group, 11% of VTs degenerated
into VF before ICD treatment was initiated. These data extend
and complete previous observations. In a study performed with
ICDs during 14 months of follow-up, Raitt et al. (30) studied
55 patients with VF as the sole documented arrhythmia at time
of resuscitation who were treated with ICDs not provided with
electrogram storage capability; they found 18% and 10%
incidences of recurrent VT and VF, respectively. Referral
modalities, a longer follow-up and the ability to recognize VT
degenerating into VF likely account for the different incidence
and distribution of ventricular arrhythmias in the present
study.
Symptoms during ventricular arrhythmias varied depending
on the cycle length of the underlying event. Syncope or
Table 3. Clinical Outcome of Patients Relative to Response at
Programmed Electrical Stimulation
VT at PES
(14 patients)
(%)
VF at PES
(7 patients)
(%)
No VA at PES
(19 patients)
(%)
VT during follow-up 5 (36) 0 (0) 6 (32)
VF during follow-up 0 (0) 1 (14) 1 (5)
PES 5 programmed electrical stimulation; VA 5 ventricular arrhythmias;
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Table 4. Clinical Outcome of Patients With Coronary Artery
Disease Relative to Response at Programmed Electrical Stimulation
VT at PES
(13 patients)
(%)
VF at PES
(4 patients)
(%)
No VA at PES
(11 patients)
(%)
VT during follow-up 4 (31) 0 (0) 3 (27)
VF during follow-up 0 (0) 0 (0) 0 (0)
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presyncope were recorded only in patients with VF or fast VT
(mean heart rate, 239 beats/min).
Clinical predictors of arrhythmia detection. No single
clinical parameter was found to predict the risk of arrhythmia
recurrence; however, it is of note that the two patients with
primary VF during follow-up were both young, had a normal
LVEF and did not have ischemic heart disease or dilated
cardiomyopathy as the underlying substrate.
Role of PES. Programmed ventricular stimulation proved
to be a poor predictor of both recurrence and type of ventric-
ular arrhythmias. A ventricular arrhythmia was inducible in
53% of patients; this finding is in agreement with previous
reports (7,13,27–29). Only 29% of patients who had a ventric-
ular arrhythmia inducible in the electrophysiology laboratory
also presented with an arrhythmia during follow-up. In the five
patients in whom a VT recurrence was predicted by PES, the
cycle length of the tachycardia in the two conditions did not
match. In addition, the one patient in whom VF was predicted
during PES had no structural heart disease. On the other hand,
47% of patients who did not have any arrhythmia inducible in
the electrophysiology laboratory developed a ventricular ar-
rhythmia during follow-up.
Underlying substrate and arrhythmia recurrence. Recur-
rence of ventricular arrhythmic events was observed in 25% of
patients with CAD, 50% of patients without structural heart
disease and 50% of patients with underlying substrates other
than CAD. In the former group of patients, VT was the only
documented arrhythmia. Although a prior myocardial infarc-
tion was documented in 86% of cases, it is of note that patients
in this study exhibited a ventricular substrate poorly amenable
to sustained and stable reentry. Suggestive of this were 1) the
clinical documentation of VF (index event), 2) the low VT
inducibility rate (35%) at PES, and 3) the fast rate of the VT
episodes recorded by stored electrograms during follow-up.
A similar mechanism may explain the occurrence of mono-
morphic VT during follow-up in other patients of this study,
such as one of four patients without organic heart disease and
three of eight patients with underlying substrates other than
CAD. Primary VF occurred in one patient without organic
heart disease and in one patient with an underlying substrate
other than CAD.
Inappropriate discharges. In this study, the incidence of
inappropriate discharges was high. Supraventricular tachycar-
dias or system failure caused one or more ICD discharges in
33% of patients, a figure in agreement with a recent review on
the limitations and late complications associated with ICD
therapy (32). The absence of concomitant antiarrhythmic drug
therapy at the time of hospital discharge certainly played a role
in the reported incidence of inappropriate discharges in this
series. Notably, 77% of patients with inappropriate discharges
were otherwise free of any ventricular arrhythmias during
follow-up. It is likely that, in the absence of telemetry, a
significant number of discharges caused by supraventricular
tachycardias or system failure would be interpreted as appro-
priate; this may account for the somewhat lower recurrence
rate of ventricular arrhythmias in this study compared with
previously published data (21).
Clinical implications. The present data show that primary
VF is not a common arrhythmic event in survivors of cardiac
arrest in whom VF is the sole documented arrhythmia at the
time of resuscitation. These patients represent a selected
group among those experiencing sudden death in the general
population. Although several factors may account for their
ability to survive such an event, it is likely that the modality of
tachycardia onset and perpetuation, as documented in this
study during recurrent ventricular arrhythmias, plays a role
(32).
We found that clinical recurrences in these patients are
characterized mostly by episodes of regular, though fast,
monomorphic VT, which, if sustained, would likely lead to
hemodynamic instability (32). On the basis of these findings,
one may speculate that at least some of these patients could
survive an episode of cardiac arrest because of the stability of
the initial arrhythmia associated with a relatively well-
preserved ventricular function. Should this be the case, the
arrhythmia recorded at the time of resuscitation would repre-
sent a degeneration of the initial arrhythmia. On the other
hand, patients with a similar or even better ejection fraction
but with primary VF, as well as those with a poor ventricular
function in the presence of a fast regular VT, would be less
likely to survive the arrhythmic episode.
Limitations. Although ICD allows analysis of the clinical
outcome free of influences on the electrophysiologic substrate
by antiarrhythmic agents, follow-up in patients receiving ICD
does not reflect the true natural history. Exacerbation of
ventricular arrhythmias during the postoperative period after
implantation (33), as well as the induction of new arrhythmias
by pacemaker interventions or inappropriate shocks (34), have
been reported and may influence the occurrence of arrhythmic
events during follow-up.
Classification of ventricular arrhythmias in the short time
between the onset of detection and redetection prevents a
distinction between sustained and nonsustained events. It also
does not allow us to establish the duration of the monomorphic
VT in the event that it eventually degenerates into VF.
Conclusions. In patients who have survived VF as the sole
documented arrhythmia at time of resuscitation and are cur-
rently receiving ICD therapy, VT is by far the most common
ventricular arrhythmia recorded on device-incorporated elec-
trograms during follow-up. Though regular, VT is generally
fast and not predictable by electrophysiologic investigation.
This finding, associated with the relatively well-preserved
ventricular function exhibited by these patients, may account
for their ability to survive at the time of the index arrhythmia.
Preliminary data obtained from similar patient populations
(35) suggest that the use of antitachycardia pacing (36) as a
modality to treat arrhythmia recurrences may contribute to
reduce the incidence of shocks during follow-up. Confirmation
in larger series of the observations made in the present study is
recommended to guide the programming modality in survivors
of VF.
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